The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric systemic lupus erythematosus

Journal of Neuroimmunology

Volumn 227, Issue 1-2, 2010, Pages 195-201

  Mostafa, Gehan A ^a   Ibrahim, Dalia H ^a   Shehab, Abeer A ^a   Mohammed, Azza K ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Anti ganglioside antibodies; Anti ribosomal P antibodies; Cognitive function; Neuropsychiatric systemic lupus erythematosus; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; GANGLIOSIDE GM1 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISOLONE; RIBOSOME PROTEIN P ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADOLESCENT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANXIETY; ARTICLE; BRAIN DISEASE; CHILD; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CONVULSION; CRANIAL NERVE INJURY; DEPRESSION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG PULSE THERAPY; FEMALE; FOCAL CONVULSION; HUMAN; MALE; MENTAL DISEASE; MONOTHERAPY; NEURITIS; NEUROLOGIC EXAMINATION; NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; AGE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; IMMUNOLOGY; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; METHODOLOGY; PREDICTIVE VALUE; STANDARDS;

ADOLESCENT; AGE FACTORS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN;

EID: 77956650937     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.07.014     Document Type: Article

References (48)

1. Abdel-Nasser A.M., Ghaleb R.M., Mahmoud J.A., Khairy W., Mahmoud R.M. Association of anti-ribosomal P antibodies with neuropsychiatric and other manifestations of systemic lupus erythematosus. Clin. Rheumatol. 2008, 27(11):1377-1385.
2. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999, 42(4):599-608.
3. Agmon-Levin N., Gilburd B., Kivity S., Katz B.S., Flitman-Katzevman I., Shoenfeld N., et al. Anti-ribosomal-P antibodies in lupus patients and healthy controls: evaluation of three ELISA assays. Isr. Med. Assoc. J. 2009, 11(7):403-406.
4. Ariga T., McDonald M.P., Yu R.K. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease-a review. J. Lipid Res. 2008, 49(6):1157-1175.
5. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Committee on Progress Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992, 35(6):630-640.
6. Caponi L., Anzilotti C., Longombardo G., Migliorini P. Antibodies directed against ribosomal P proteins cross-react with phospholipids. Clin. Exp. Immunol. 2007, 150(1):140-143.
7. Carbotte R.M., Denburg S.D., Denburg J.A. Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J. Rheumatol. 1995, 22(5):863-867.
8. Castellino G., Govoni M., Giacuzzo S., Trotta F. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun. Rev. 2008, 7(4):297-304.
9. Colasanti T., Delunardo F., Margutti P., Vacirca D., Piro E., Siracusano A., et al. Antibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus. J. Neuroimmunol. 2009, 212(1-2):3-9.
10. Costallat L.T.L., Oliveira R.M., Santiago M.B. Neuropsychiatric manifestations of systemic lupus erythematosus: the value of anti-cardiolipin, anti-gangliosides and anti-galactocerebrosides antibodies. Clin. Rheumatol. 1990, 9:489-497.
11. Efthimiou P., Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod. Rheumatol. 2009, 19(5):457-468.
12. Galaezzi M., Annunziata P., Sebastiani G.D., Bellisai F. Anti-ganglioside M1 IgM antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological and HLA class II gene association. J. Rheumatol. 2000, 27(1):135-141.
13. Greenwood D.L., Gitlits V.M., Alderuccio F., Sentry J.W., Toh B.H. Auto-antibodies in neuropsychiatric lupus. Autoimmunity 2002, 35(2):79-86.
14. Hanly J.G., McCurdy G., Fougere L., Douglas J.A., Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J. Rheumatol. 2004, 31(11):2156-2162.
15. Hanly J.G., Su L., Farewell V., McCurdy G., Fougere L., Thompson K. Prospective study of neuropsychiatric events in systemic lupus erythematosus. J. Rheumatol. 2009, 36(7):1449-1459.
16. Heinlen L.D., McClain M.T., Merrill J., Akbarali Y.W., Edgerton C.C., Harley J.B., James J.A., et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007, 56(7):2344-2351.
17. Hermosillo-Romo D., Brey R.L. Diagnosis and managements of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). Best Pract. Res. Clin. Rheumatol. 2002, 16(2):229-244.
18. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40(9):1725.
19. Kajs-Wyllie M.K. Lupus cerebritis: a case study. J. Neurosci. Nurs. 2002, 34(4):176-183.
20. Karassa F., Loaunidis J.P., Boki K. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am. J. Med. 2000, 109:628-634.
21. Kato T., Hatanaka K. Purification of gangliosides by liquid-liquid partition chromatography. J. Lipid Res. 2008, 49(11):2474-2478.
22. Khedr E.M., Khedr T., Farweez H.M., Abdella G., El Beih E.A. Multimodel electroneurophysiological studies of systemic lupus erythematosus. Neuropsychobiology 2001, 43(3):204-212.
23. Martinez X., Tintoré M., Montalbán J., Ordi J., Vilardell M., Codina A. Antibodies against gangliosides in patients with SLE and neurological manifestations. Lupus 1992, 1(5):299-302.
24. Meleka L.K., Ismail M.E. Arabic Translation of Wechsler Intelligence Scale for Children 1999, Egyptian Anglo library, Cairo. 6th edn.
25. Morton D.L. Human antiganglioside antibodies: validation of ELISA. Ann. NY Acad. Sci. 2005, 1050:229-242.
26. Mostafa G.A., Nazif H.K., El-Shehawy H.H., Abd El Aziz M.M., Hassan M.A. Antineuronal antibodies and electroneurophysiological studies in pediatric patients with neuropsychiatric systemic lupus erythematosus. Pediatr. Allergy Immunol. 2009, 20(2):192-199.
27. Navarrete M.G., Brey R.L. Neuropsychiatric systemic lupus erythematosus. Curr. Treat. Options Neurol. 2000, 2(5):473-485.
28. Nived O., Sturfelt G., Liang M.H., De Pablo P. The ACR nomenclature for CNS lupus revisited. Lupus 2003, 12:872-876.
29. Olazarán J., López-Longo J., Cruz I., Bittini A., Carreño L. Cognitive dysfunction in systemic lupus erythematosus: prevalence and correlates. Eur. Neurol. 2009, 62(1):49-55.
30. Plomp J.J., Willison H.J. Pathophysiological actions of neuropathy-related anti-ganglioside M1 IgM antibodies at the neuromuscular junction. J. Physiol. 2009, 587(Pt 16):3979-3999.
31. Ravindranath M.H., Muthugounder S., Saravanan T.S., Presser N., Morton D.L. Human antiganglioside antibodies: validation of ELISA. Ann. NY Acad. Sci. 2005, 1050:229-242.
32. Ribeiro C.M., Vasconcelos B.C., Silva Neto J.C., Silva Júnior V.A., Figueiredo N.G. Histopathological analysis of gangliosides use in peripheral nerve regeneration after axonotmesis in rats. Acta Cir. Bras. 2008, 23(4):364-371.
33. Sanna G., Bertolaccini M.L., Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003, 12(12):935-942.
34. Sany-Choel B.A.E. The ACR classification of neuropsyohiatric systemic lupus erythematosus: how this helps in diagnosis and treatment. APLAR J. Rheumatol. 2003, 6:188-191.
35. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):22-33.
36. Sibbitt W.L., Brandt J.R., Johnson C.R., Maldomado M.E., Patel S.R., Ford C.C. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J. Rheumatol. 2002, 29(7):1536-1542.
37. Stojanovich L., Zandman-Goddard G., Pavlovich S. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun. Rev. 2007, 6(6):421-426.
38. Sugiura Y., Shimma S., Konishi Y., Yamada M.K., Setou M. Imaging mass spectrometry technology and application on ganglioside study; visualization of age-dependent accumulation of C20-ganglioside molecular species in the mouse hippocampus. PLoS ONE 2008, 3(9):e3232.
39. Teh L.S. Neuropsychiatric systemic lupus erythematosus (NPSLE). CPD Rheumatol. 2003, 3(3):77-81.
40. Tzioufas A.G., Tzortzakis N.G., Panou-Pomonis E., Boki K.A., Sakarellos-Daitsiotis M., Sakarellos C., et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann. Rheum. Dis. 2000, 59(2):99-104.
41. Vojdani A., Campbell A.W., Anyanwu E., Kashanian A., Bock K., Vojdani E. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J. Neuroimmunol. 2002, 129(1-2):168-177.
42. Watanabe O., Arimura K. Pathomechanism of autoantibody production in neurological disorders. Nippon Rinsho 2008, 66(6):1065-1072.
43. Wechsler D. Wechsler Intelligence Scale for Children 1991, Psychological Corporation. Harcourt Brace and Company Publishers, New York. 3rd edn.
44. Yoshida A., Shishido F., Kato K. Evaluation of cerebral perfusion in patients with neuropsychiatric systemic lupus erythematosus using 1231-Imp spect. Ann. Nucl. Med. 2007, 21(3):151-158.
45. Yoshio T., Masuyama J., Ikeda M., Tamai K., Hachiya T., Emori T., et al. Quantification of antiribosomal PO protein antibodies by ELISA with recombinant PO fusion protein and their association with central system disease in systemic lupus erythematosus. J. Rheumatol. 1995, 22:1681-1687.
46. Zitman F.M., Todorov B., Jacobs B.C., Verschuuren J.J., Furukawa K., Furukawa K., et al. Neuromuscular synaptic function in mice lacking major subsets of gangliosides. Neuroscience 2008, 156(4):885-897.
47. Zitman F.M., Todorov B., Verschuuren J.J., Jacobs B.C., Furukawa K., Furukawa K., et al. Neuromuscular synaptic transmission in aged ganglioside-deficient mice. Neurobiol. Aging 2009, Feb 20 [Epub ahead of print].
48. Zitman F.M., Todorov B., Furukawa K., Furukawa K., Willison H.J., Plomp J.J. Total ganglioside ablation at mouse motor nerve terminals alters neurotransmitter release level. Synapse 2010, 64(4):335-338.